IDH2 and glioma: In a study including 127 patients (48% of patients had IDH-mutant gliomas), Maurer and colleagues reported that the combined analysis of static and dynamic FET PET parameters achieved an overall accuracy of 81% for the differentiation of treatment-related changes from tumor progression [69].